Your address will show here +12 34 56 78
Featured, Market Study

Pharmaceutical Industry

The Covid-19 pandemic thrust the pharmaceutical industry into the spotlight, intensifying the pressure to deliver swift results. Since, companies faced a host of challenges.

The pharma’s role within the healthcare system is weakening due to:

–  A sudden surge in demand which encourages research and development, but that implies high financial burden

–  Economic strains,

– Suffocating regulatory change.

To remain profitable, pharmaceutical companies need to change their operational strategy as the industry faces new challenges. This is what LloydsPharmacy, once the 2nd largest pharmacy chain in the UK, did but faced with a cliff edge.

LloydsPharmacy, which was founded in 1973, had a significant potential.

Ownership history:

Over the past decade LloydsPharmacy (Clinical Homecare, LloydsDirect, Lloyds Online Doctor and a wholesale AHH) had many owners.

– In 1973, Lloyds Chemist began when Allen Lloyd purchased his 1st pharmacy in Polesworth (UK).

– In 1997, LloydsPharmacy was purchased by Celesio AG and merged with Celesio’s existing UK subsidiary, AAH Pharmaceuticals, forming a network of 1300 pharmacies.

– In 2014, the american healthcare company McKesson acquired Celesio AG, becoming the parent company of LloydsPhharmacy along with its other units: LloydsPharmacy Clinical Homecare, LloydsDirect, Lloyds Online Doctor, and a wholesale arm called AHH.

– In April 2022, McKesson’s UK businesses, including LloydsPharmacy, the wholesaler AAH, and a travel health service, were purchased by the Aurelius Group for £477m.

Transforming the company:

LloydsPharmacy became an omnichannel company platform. This strategy was validated with the significant growth across its online offering during the pandemic.

After the purchase by Aurelius Group, as a result, LloydsPharmacy joined the Hallo Healthcare Group, the holding company brand name for some of the UK’s most renowned healthcare organizations.

So, how did a business which had 1,338 stores at the end of 2022, just a over year later disappear from the high street.

LloydsPharmacy began to exit the pharmacy market, since 2017 due to:

– Government funding cuts

– Higher operating costs.

The chain swung to a pre-tax loss of £148m in the year to 31 March 2017.

The closures began in 2017 and continued with 17 stores in 2018, 60 in 2019, 76 in 2021 and 41 in 2022.

According to the Companies House, for the year ending March 31, 2022, Lloyds Pharmacy recorded further losses, with:

– operating losses worsening from £-35m to £-57m,

– net losses of £-66m, down from £100.8 million the previous year.

The company stepped up its « rationalization program » in 2023. In October 2023, the chain was running 138 pharmacies, compared with 1,338 pharmacies in March 2022 (-90%), according to the figures of General Pharmaceutical Council (CPhC).

In July 2015, LloydsPharmacy purchased all 281 pharmacies in Sainsbury’s supermarkets for £125 million but decided to close all in January 2023.


LloydsPharmacy filed for voluntary liquidation and blamed the cut in government funding for its widening losses and the reason behind its store rationalization program. 

In 2023, the chain ceased trading, with pharmacy staff transferred to their stores’ new operators.

In the statement of affairs report, the liquidators (Martin Armstrong and Andrew Bailey of Turpin Barker Armstrong Accountants) revealed that the pharmacy business owed £293m to 514 creditors, including:

– £228m owed to Diamond DCO One Limited /Lloyds Pharmacy,

– £50m owed to Aurelius Crocodile, a holding company used to control the business.

However, the financial documents show that as LloydsPharmacy had just £8.2m at its disposal to pay off its debts.

As a conclusion The pharmaceutical industry has faced challenges in recent years:

Low Margins & Diversification

Due to low margins on medications, pharmacies are expanding their offerings to include non-prescription products (parapharmacy). But this expansion requires additional investments.

Competition Risks & Regulation

In fact, the distribution of medications is deregulated, allowing mass-market retailers to enter the sector. It will intensify competition for pharmacies

LloydsPharmacy serves as a notable example. Today, the pharmaceutical industry will need to anticipate these risks and protect itself against the risk of non-payment.


Featured, Solutions

Gaining new markets, especially export markets, is a unique opportunity to develop your sales. But it’s not without risk for your company.

Starting a business relationship with a new customer, or increasing your sales with an existing one, requires special care and the implementation of “safeguards”.

Whether it’s an existing customer or a new one, when you’re dealing with an international customer, the financial information is more complex to obtain, the dunning and collection procedures more sensitive, and your knowledge of the economic environment murkier.

This is especially true as international payment terms extend over longer periods. This is a risk you need to be aware of before taking on a new market.

Transferring the risk

However, there are effective solutions for transferring this risk to a credit insurer, offering essential protection for the sustainable growth of your company.

Unlock Focus allows you to benefit from complete support including information, risk monitoring, credit limit stability and collection, to secure a key transaction for your company. By opting for Cartan Trade’s Unlock Focus contract, your company is protected against the insolvency of the end buyer.

In the event of bankruptcy of the buyer during the period of manufacturing or in the event of non-payment of the goods on the due date of the invoice, your company is swiftly compensated by Cartan Trade, thus preserving your cash flow.

Being insured against unpaid invoices also gives your company the opportunity to benefit from optimised financing. Indeed, lending organisations are often more inclined to grant loans or credit lines when a transaction is covered by credit insurance.

Discover all the advantages of Cartan Trade’s Unlock Focus solution

In a nutshell, transferring the risk of non-payment to a credit insurer is an effective solution to increase your turnover with peace of mind in an unpredictable commercial environment, while protecting your company from financial losses due to customer non-payment. More info about Unlock Focus.

Unlock Focus is also available in a ‘Multi’ version to cover your outstanding amounts on your strategic customers, on a revolving basis over 12 months or in the event of business peaks when your internal credit limit is reached.

Discover Unlock Multi